Every company in this category will tell you how much weight its members lost. 9amHealth tells you how much they lost without the drug as well — and that second number is the most useful thing published by anyone we have reviewed.
The Comparison Nobody Else Publishes
The headline figures are 17.6% weight reduction with GLP-1s over twelve months and 9.3% without GLP-1s over the same period.
Think about what it takes to publish that second number. 9amHealth sells a programme that includes medication, and it has voluntarily disclosed that people who used the programme without medication still lost 9.3% — which is most of the way to a clinically meaningful result, and an argument for spending less money with them.
Almost nobody does this. Across this whole review set, the standard is a single number chosen to be flattering, with no comparison group at all. A reader given “17.6%” alone cannot tell how much of it came from the drug and how much from the coaching, the labs, the dietitian or simply from the kind of person who signs up for a metabolic programme. Publishing both lets you see the gap.
The 17.6% figure is also credible on its face. It sits between semaglutide’s roughly 15% and tirzepatide’s roughly 21% in their registration trials, which is where a real-world mixed-medication population ought to land. A company inventing a number would have picked a rounder, larger one.
Two further figures are reported: a 2.8 point A1c reduction among members starting above 9%, and a 19.8 mmHg blood pressure reduction. The A1c figure is properly qualified — it names the starting population, which is the detail that makes a glycaemic result interpretable, since people starting higher have more room to fall.
What the Comparison Cannot Tell You
Having praised it, the comparison is not a trial and should not be read as one. These are internal, self-reported, non-randomised figures, and nobody was assigned to a group by chance.
The two groups almost certainly differ systematically. People who end up on a GLP-1 are typically those with a higher starting weight or a metabolic indication — and heavier starting points tend to produce larger percentage losses. Meanwhile the no-medication group is partly self-selected for people who were doing well enough not to need one. Those two effects push the gap in opposite directions, and without knowing the composition of each group you cannot say what the true difference is.
No sample size, denominator, or definition of who was counted is published either, and there is no statement about whether these are completers or everyone who enrolled. On the evidence ladder we use across these reviews, this is still company-reported internal data — the same rung as knownwell and Enara Health. It is simply the most honestly constructed version of that rung we have found, because it includes the number that makes the company look less essential.
A Credential You Can Check
The care team is described as including board-certified obesity medicine specialists — physicians holding DABOM, the American Board of Obesity Medicine diplomate credential — alongside endocrinologists, pharmacists, dietitians and behavioural health experts.
Naming the specific credential matters. “Expert clinicians” and “licensed providers” are unfalsifiable; DABOM is a real subspecialty certification with an exam behind it, and a named diplomate can be verified. Most of this category is staffed by generalist prescribers working from a protocol, so a team built around obesity medicine and endocrinology is a genuine differentiator — particularly given that 9amHealth treats diabetes and cardiometabolic disease alongside weight, where the endocrinology matters.
Labs and Devices
The programme includes at-home lab tests, connected devices for monitoring, personalised care plans covering nutrition and exercise, and its own pharmacy services with medication shipped to the home.
That is a real measurement infrastructure, and it separates 9amHealth from the large part of this market that prescribes on the strength of a questionnaire and never measures anything. At-home collection removes a genuine barrier, and connected devices mean blood glucose and blood pressure are tracked continuously rather than recalled at an appointment. It is also what makes the published A1c and blood pressure figures possible at all — a company can only report those numbers if it is collecting them.
No Prices, No Medications, No States
For a company this careful about clinical detail, the commercial disclosure is disappointing. No pricing appears anywhere — not for membership, consultations, labs or medication.
It also does not name a single medication, and does not say whether what it dispenses is compounded or brand-name — the question that most determines both cost and regulatory status, and one our compounded versus brand-name guide covers. A company running its own pharmacy services should find that an easy question to answer.
No BMI or eligibility criteria, insurance position, HSA/FSA status or list of states served is published either. The result is a service you can evaluate clinically but not commercially, which is an unusual way round — and still leaves you unable to decide whether to buy it.
Provider Facts
| Medications offered | Prescription medication when clinically indicated, including GLP-1s; no individual drugs named |
|---|---|
| Brand-name or compounded | Not stated - the site does not say whether medication is compounded or brand-name |
| Consultation process | Virtual access to the clinical team; format, length and cost not published |
| Eligibility | Not published - no BMI threshold stated |
| Provider involvement | Board-certified obesity medicine specialists holding DABOM, plus endocrinologists, pharmacists, dietitians and behavioural health experts |
| Lab requirements | At-home lab testing included, with connected devices for ongoing monitoring |
| Pharmacy fulfillment | Own pharmacy services, shipping medication to the home; compounding partners not named |
| Shipping frequency | Medication shipped to the home; timings not published |
| Support services | Personalised care plans covering nutrition and exercise, plus behavioural health support |
| Membership fees | Not published |
| Medication fees | Not published |
| Cancellation policy | Not published |
| Refund policy | Not published |
| Insurance | Not published |
| HSA/FSA | Not published |
| Availability | Not published - no state list found |
Pros and Cons
Pros
- Publishes outcomes with and without GLP-1s — unique in our review set
- The 17.6% figure is consistent with the trial literature rather than above it
- Qualifies its A1c result by naming the starting population
- Names a real, verifiable credential in DABOM rather than saying “experts”
- Endocrinologists, pharmacists and dietitians on the team, not just prescribers
- At-home labs and connected devices mean it actually measures things
- Treats diabetes and cardiometabolic disease alongside weight
Cons
- No pricing published for anything
- Never names a single medication
- Does not say whether medication is compounded or brand-name
- Outcome figures are internal, non-randomised and carry no sample size
- The two comparison groups are not like-for-like
- No states, BMI criteria, insurance or HSA/FSA detail
Who It May Be Best For
A strong fit if you have type 2 diabetes or a cardiometabolic condition alongside weight. This is a clinic organised around that combination, with endocrinologists and real monitoring, rather than a weight-loss shop that also happens to mention blood sugar.
Worth considering if you want to know whether you actually need the medication. A programme willing to publish its non-medication result is more likely to give you a straight answer about starting without one.
Get the full cost in writing before enrolling — membership, labs, consultations and medication — plus which drug you would receive and whether it is compounded. None of it is published.
Alternatives
knownwell is the closest peer — obesity medicine certified and insurance-billed. Virta Health takes the nutrition-first route with a peer-reviewed citation. Enara Health runs a comparable multidisciplinary programme. Our best GLP-1 for weight loss page compares the field.
Limitations of This Review
Based on 9amHealth’s own published materials, checked on 6 September 2026 at join9am.com, to which 9am.health redirects. Every outcome figure is the company’s own reporting and we could not verify any of it; our analysis addresses how the figures are constructed rather than asserting they are wrong. Anything marked not published means we could not find it — pricing and medication detail are likely disclosed during an enrolment process we did not complete. Trial comparison figures for semaglutide and tirzepatide come from the published literature, not from 9amHealth. Nothing here is medical advice.
Frequently Asked Questions
What do the 17.6% and 9.3% figures mean?
They are 9amHealth’s own twelve-month results for members who used GLP-1 medication and members who did not. They are not a randomised comparison — the groups differ systematically — but publishing both is far more informative than a single number.
What is DABOM?
Diplomate of the American Board of Obesity Medicine — a real subspecialty certification with an examination behind it, and one you can verify for a named physician. It is uncommon in GLP-1 telehealth, where generalist prescribers are the norm.
What does 9amHealth cost?
Not published. Neither membership, consultations, labs nor medication carry a price on the site, and no insurance or HSA/FSA position is stated. Ask for a full breakdown before enrolling.
Which GLP-1 does it prescribe?
The site does not name any medication, or say whether it is compounded or brand-name. Given it runs its own pharmacy services, that is worth asking directly.
Verdict
3.8 / 5 — no pricing published
Clinically one of the more serious operations here — obesity medicine specialists, endocrinologists, real labs and devices — and the only one that published the number making its own product look less necessary. It tells you almost nothing about what any of it costs.
The point worth carrying beyond this provider: when a company publishes a result that weakens its own sales pitch, take the rest of its numbers more seriously. Selective reporting is the default in this market, and the cheapest way to spot a company that is not doing it is to look for the inconvenient figure. 9amHealth printed theirs.
Medical Disclaimer & Review Date
This review is general consumer information, not medical advice. GLP-1 medications are prescription drugs with serious contraindications, and whether any treatment is appropriate for you is a decision only a licensed healthcare provider who knows your medical history can make. Nothing here should be used to start, stop, or change a medication.
Details in this review come from 9amHealth's own published materials as of the date below. Pricing, medication availability, state coverage, and policies in this category change frequently — verify current terms directly with the provider before purchasing.
Date reviewed: September 6, 2026